acetylcarnitine has been researched along with Cognition Disorders in 15 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the putative neurotherapeutic effects of the mitochondrial cofactors, L-carnitine, acetyl-L-carnitine, and alpha-lipoic acid; and to provide a rationale for investigating their efficacy in the treatment of neurocognitive deficits associated with mood disorders." | 8.84 | Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? ( Chow, CS; Kennedy, SH; Konarski, JZ; McIntyre, RS; Soczynska, JK; Woldeyohannes, HO, 2008) |
| "Mood disorders are associated with decrements in cognitive function, which are insufficiently treated with contemporary pharmacotherapies." | 6.44 | Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? ( Chow, CS; Kennedy, SH; Konarski, JZ; McIntyre, RS; Soczynska, JK; Woldeyohannes, HO, 2008) |
| "To evaluate the putative neurotherapeutic effects of the mitochondrial cofactors, L-carnitine, acetyl-L-carnitine, and alpha-lipoic acid; and to provide a rationale for investigating their efficacy in the treatment of neurocognitive deficits associated with mood disorders." | 4.84 | Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? ( Chow, CS; Kennedy, SH; Konarski, JZ; McIntyre, RS; Soczynska, JK; Woldeyohannes, HO, 2008) |
| "ALC slows the progression of Alzheimer's disease in younger subjects, and the use of the trilinear approach to estimate the average rate of change may prove valuable in pharmacological trials." | 2.69 | Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. ( Bravi, D; Brooks, JO; Carta, A; Yesavage, JA, 1998) |
| "People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population." | 2.52 | Pharmacological interventions for cognitive decline in people with Down syndrome. ( Hanratty, J; Livingstone, N; Macdonald, G; McShane, R, 2015) |
| "Mood disorders are associated with decrements in cognitive function, which are insufficiently treated with contemporary pharmacotherapies." | 2.44 | Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? ( Chow, CS; Kennedy, SH; Konarski, JZ; McIntyre, RS; Soczynska, JK; Woldeyohannes, HO, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pennisi, M | 1 |
| Lanza, G | 1 |
| Cantone, M | 1 |
| D'Amico, E | 1 |
| Fisicaro, F | 1 |
| Puglisi, V | 1 |
| Vinciguerra, L | 1 |
| Bella, R | 1 |
| Vicari, E | 1 |
| Malaguarnera, G | 1 |
| Bigford, GE | 1 |
| Del Rossi, G | 1 |
| Mehrotra, A | 1 |
| Kanwal, A | 1 |
| Banerjee, SK | 1 |
| Sandhir, R | 1 |
| Snigdha, S | 1 |
| de Rivera, C | 1 |
| Milgram, NW | 1 |
| Cotman, CW | 1 |
| Livingstone, N | 1 |
| Hanratty, J | 1 |
| McShane, R | 1 |
| Macdonald, G | 1 |
| Suchy, J | 1 |
| Chan, A | 1 |
| Shea, TB | 1 |
| Glade, MJ | 1 |
| Malaguarnera, M | 1 |
| Soczynska, JK | 1 |
| Kennedy, SH | 1 |
| Chow, CS | 1 |
| Woldeyohannes, HO | 1 |
| Konarski, JZ | 1 |
| McIntyre, RS | 1 |
| Pascale, A | 1 |
| Milano, S | 1 |
| Corsico, N | 1 |
| Lucchi, L | 1 |
| Battaini, F | 1 |
| Martelli, EA | 1 |
| Trabucchi, M | 1 |
| Govoni, S | 1 |
| Brooks, JO | 1 |
| Yesavage, JA | 1 |
| Carta, A | 1 |
| Bravi, D | 1 |
| Kidd, PM | 1 |
| Herrmann, WM | 1 |
| Stephan, K | 1 |
| Tempesta, E | 1 |
| Troncon, R | 1 |
| Janiri, L | 1 |
| Colusso, L | 1 |
| Riscica, P | 1 |
| Saraceni, G | 1 |
| Gesmundo, E | 1 |
| Calvani, M | 1 |
| Benedetti, N | 1 |
| Pola, P | 1 |
| Bonavita, E | 1 |
7 reviews available for acetylcarnitine and Cognition Disorders
| Article | Year |
|---|---|
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.
Topics: Acetylcarnitine; Brain; Cognition; Cognition Disorders; Dementia; Humans; Liver; Nootropic Agents; T | 2020 |
Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders.
Topics: Acetylcarnitine; Alzheimer Disease; Brain; Brain Injuries; Cinnamates; Cognition Disorders; Curcumin | 2014 |
Pharmacological interventions for cognitive decline in people with Down syndrome.
Topics: Acetylcarnitine; Adult; Antioxidants; Cognition; Cognition Disorders; Donepezil; Down Syndrome; Huma | 2015 |
Oxidative stress and cognitive longevity.
Topics: Acetylcarnitine; Aging; Animals; Central Nervous System; Cognition; Cognition Disorders; Humans; Lon | 2010 |
Carnitine derivatives: clinical usefulness.
Topics: Acetylcarnitine; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Cognition Disorders; Depres | 2012 |
Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
Topics: Acetylcarnitine; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carnitine; Cl | 2008 |
A review of nutrients and botanicals in the integrative management of cognitive dysfunction.
Topics: Acetylcarnitine; Cognition Disorders; Complementary Therapies; Dementia; Ginkgo biloba; Humans; Noot | 1999 |
4 trials available for acetylcarnitine and Cognition Disorders
| Article | Year |
|---|---|
Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach.
Topics: Acetylcarnitine; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Disea | 1998 |
Efficacy and clinical relevance of cognition enhancers.
Topics: Acetylcarnitine; Clinical Trials as Topic; Cognition; Cognition Disorders; Dementia; Humans; Nimodip | 1991 |
Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism.
Topics: Acetylcarnitine; Adult; Alcoholism; Carnitine; Clinical Trials as Topic; Cognition Disorders; Double | 1990 |
Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Anxiety Disorders; Carnitine; Cognition Disorders; Depress | 1986 |
4 other studies available for acetylcarnitine and Cognition Disorders
| Article | Year |
|---|---|
Mitochondrial modulators in experimental Huntington's disease: reversal of mitochondrial dysfunctions and cognitive deficits.
Topics: Acetylcarnitine; Animals; Cognition Disorders; Drug Therapy, Combination; Female; Huntington Disease | 2015 |
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Topics: Acetylcarnitine; Aging; Animal Nutritional Physiological Phenomena; Animals; Antioxidants; Coenzymes | 2016 |
Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance.
Topics: Acetylcarnitine; Alzheimer Disease; Animals; Antioxidants; Apolipoproteins E; Cognition Disorders; D | 2009 |
Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: in vitro and in vivo studies.
Topics: Acetylcarnitine; Amnesia; Animals; Cerebral Cortex; Cognition Disorders; Dose-Response Relationship, | 1994 |